Understanding a Streamlined Approach to Good Manufacturing Practice: Device-Sided vs. Drug-Sided Pathways in FDA’s CGMP Guidance
Combination products such as drug-coated stents, prefilled syringes, and wearable injectors combine drug, device, and sometimes biologic components into a single product. While these products provide important therapeutic advantages, they also present unique regulatory challenges.
To address these challenges, the FDA issued its Guidance for Industry and FDA Staff on Current Good Manufacturing Practice (CGMP) Requirements for Combination Products under 21 CFR Part 4. This regulation establishes how manufacturers must comply with CGMPs when a product integrates components regulated under different frameworks.
Under Part 4, manufacturers have two primary compliance options:
- Full Dual Compliance – Independently implementing and complying with both drug CGMPs (21 CFR Parts 210/211) and device Quality System Regulation (21 CFR Part 820) in their entirety. This may also be done with a single, integrated quality system that fully incorporates both the drug CGMPs and device Quality System Regulation in their entirety.
- The Streamlined Approach – Operating under a single, integrated quality system by choosing either the drug CGMPs (21 CFR Parts 210/211) or the device QSR (21 CFR Part 820) as the base framework in which demonstrates full compliance. The framework is then supplemented with the specific additional provisions from the other set of requirements identified in Part 4. This approach avoids unnecessary duplication while ensuring full compliance with both the drug and device frameworks.
This blog focuses on the streamlined approach, examining how it can be applied from either the device side (a device-based quality system supplemented with drug CGMP provisions) or the drug side (a drug-based quality system supplemented with device QSR provisions).
Device-Side Streamlined Approach
When a manufacturer’s foundation is already device-focused (e.g., stents, pumps, catheters), the streamlined path means maintaining compliance with 21 CFR Part 820 and supplementing it with the most critical drug CGMP requirements from Parts 210 and 211.
Additional Drug CGMP Provisions Required
- Testing and Approval or Rejection of Components, Drug Product Containers, and Closures
- All incoming materials (active ingredients, excipients, packaging, and container-closure systems) must be sampled, tested, and either approved or rejected before use.
- Prevents use of substandard or contaminated materials.
- Calculation of Yield
- Requires accurate calculation of theoretical vs. actual yield at each production stage.
- Helps ensure no unexplained losses (which could mean contamination, mislabeling, or mix-ups)
- Stability Testing
- Manufacturers must ensure the drug component maintains its safety, identity, strength, quality, and purity over its shelf life.
- For example, in a drug-eluting stent, stability studies confirm that the coating remains effective during storage.
- Sterility & Sterile Processing
- If sterility is required (e.g., for injectables), the streamlined device-based system must integrate aseptic processing and sterility testing provisions.
- This often means adopting cleanroom protocols beyond what is standard for device-only operations.
- Expiration Dating
- Labeling must reflect scientifically justified expiration dating.
- Device-only firms must build the capability to determine and support shelf life for the drug component.
- Testing & Release for Distribution
- Drug product lots must undergo identity and quality testing prior to release.
- Device firms may need to expand laboratory controls and batch record reviews.
- Tamper-evident packaging requirements for over-the-counter (OTC) human drug products.
- OTC drugs must be in tamper-evident packaging with a visible barrier or indicator.
- Labels must describe the feature so consumers know what to look for.
- A safeguard against product tampering in distribution.
- Special testing requirements.
- Certain drug products (e.g., sterile, pyrogen-free, antibiotics) have unique safety/quality tests mandated.
- Ensures critical attributes are verified.
- Reserve samples.
- Manufacturers must retain reserve samples of both active ingredients and finished products.
- Samples are kept for potential future quality checks, FDA investigations, or customer complaints.
Drug-Side Streamlined Approach
For companies grounded in pharmaceutical operations (e.g., injectables, oral drugs), the streamlined path means maintaining compliance with 21 CFR Parts 210 and 211 and supplementing with essential device QSR provisions from Part 820.
Additional Device QSR Provisions Required
- Management Responsibility
- Senior management must demonstrate accountability for the overall quality system, including device-related risks.
- Management reviews should cover device complaints, CAPA actions, and post-market device data.
- Design Controls
- A major addition for drug firms. Device design control requirements ensure systematic development based on user needs, risk analysis, verification, and validation.
- Example: For a prefilled injector, design validation includes human factors testing to confirm patients can use the device safely.
- Corrective and Preventive Action (CAPA)
- CAPA systems must extend beyond drug deviations to capture device issues like mechanical failures or usability complaints.
- A single CAPA framework can integrate both.
- Purchasing Controls
- Supplier qualification and monitoring must consider device-specific risks.
- Drug firms sourcing device components (e.g., syringes, auto-injectors) need to evaluate suppliers not just for material quality but also for design reliability.
- Installation
- Requires documented procedures for installing devices correctly, and verification that they function as intended.
- Ensures safe and proper setup of combination products that require installation.
- Servicing
- Requires written procedures for device servicing and recordkeeping. Service data must be reviewed for trends and problems.
- Ensures that products needing maintenance (e.g., pumps, delivery systems) remain safe and effective throughout use.
Comparing the Two Paths
Benefits of Both Streamlined Approaches
- Elimination of Redundancy
- Instead of duplicating systems, both approaches allow a single framework to meet requirements.
- Regulatory Clarity
- FDA inspectors can review one system rather than juggling parallel processes.
- Cross-Functional Collaboration
- Teams work together within a unified system, reducing silos between device engineers and pharma scientists.
- Scalability
- Once in place, streamlined systems can adapt easily to new combination products.
Challenges to Anticipate
- Integration Complexity: Both paths require careful mapping to ensure no requirement is overlooked.
- Training Needs: Staff must learn requirements outside their traditional areas (drug teams learning design controls, device teams learning sterility testing).
- Inspection Readiness: FDA will test whether the streamlined system truly integrates both sets of rules.
Best Practices for Implementation
- Perform a Gap Analysis
- Compare your base system against the “missing” requirements from the other side.
- Develop Traceability Documentation
- Explicitly map where each requirement is covered in your streamlined system.
- Invest in Training
- Build team literacy in both drug and device CGMPs.
- Pilot on a Single Product
- Refine SOPs and integration processes before rolling out system-wide.
- Engage Regulators Early
- Use pre-submission meetings to confirm your streamlined strategy.
Non-FDA Example Case Studies for a Streamlined Approach
Case Study 1: Device-Side Streamlined System, Drug-Eluting Coronary Stent
Background:
A cardiovascular device company, historically focused on medical stents, develops a drug-eluting coronary stent. Their quality system already complies with 21 CFR Part 820 (QSR), covering design controls, CAPA, supplier management, and production controls.
Challenge:
Adding a drug coating introduces obligations under 21 CFR Parts 210/211. Rather than running two full systems, the company adopts the streamlined approach under 21 CFR Part 4.
Implementation Steps:
- Stability Testing: The firm establishes a program to monitor drug release characteristics and long-term stability under defined storage conditions.
- Sterility & Aseptic Practices: Cleanroom protocols are added to ensure the sterility of both the stent and drug coating.
- Expiration Dating: Expiration dates are justified through stability data, a new requirement for this device-oriented manufacturer.
- Batch Release Testing: The company introduces lot testing for drug identity, strength, quality, and purity before release.
Outcome:
By supplementing their robust device QSR system with key drug CGMP elements, the company achieves full compliance under a single, streamlined quality system. This reduces duplication, ensures regulatory alignment, and strengthens confidence in product safety and performance.
Case Study 2: Drug-Side Streamlined System, Prefilled Syringe with Biologic
Background:
A biologics manufacturer, experienced with sterile injectable products, develops a prefilled syringe containing an antibody. Their operations are firmly rooted in 21 CFR Parts 210/211 (drug CGMPs), which cover laboratory controls, sterility assurance, and batch release.
Challenge:
Because the product includes a syringe delivery system, device QSR provisions apply. Instead of building a separate device quality system, the firm opts for the streamlined approach.
Implementation Steps:
- Management Responsibility: Leadership expands oversight to include device-specific risks, ensuring quality reviews cover both biologic and syringe performance data.
- Design Controls: A design history file is established for the syringe, including human factors studies to confirm patients can administer doses safely.
- CAPA System: The existing deviation system is broadened into a CAPA framework that captures both biologic issues (e.g., potency loss) and device complaints (e.g., plunger malfunction).
- Purchasing Controls: Supplier qualification expands to syringe component vendors, requiring evaluation of material integrity, device design reliability, and sterilization compatibility.
Outcome:
The company maintains its strong drug CGMP system while layering in the critical device QSR elements. The unified streamlined framework ensures full compliance, supports smoother FDA inspections, and reduces operational burden by avoiding parallel systems.
Conclusion
Section IV of the FDA’s CGMP Guidance provides flexibility in compliance. The streamlined approach allows manufacturers to integrate requirements into a single system, but the path taken depends on whether the foundation is device-based or drug-based.
- Device companies must add drug-focused provisions like stability, sterility, expiration dating, and release testing.
- Drug companies must add device-focused provisions like management responsibility, design controls, CAPA, and purchasing controls.
Either path leads to the same destination: an efficient, unified quality system that satisfies regulators, safeguards patients, and supports innovation in combination products.
At Ventura Solutions, we specialize in helping medical device and combination product companies navigate complex challenges throughout all stages of development. Whether you need end-to-end support with an integrated device team, quality or regulatory consulting, assistance with DHF remediation, additional staffing needs, employee training, or more; our team of experts are ready to help. Contact us today.
Interested in learning more about medical device and combination product development? Subscribe to our newsletter below for expert insights, the latest developments in medical device and combination product space, and exciting career opportunities!
